.Basilea Pharmaceutica's work creating new antifungals has received a notable improvement coming fro...
.Possessing presently gathered up the U.S. liberties to Capricor Rehabs' late-stage Duchenne muscula...
.After pushing back the selection meeting for Applied Rehabs' metabolic ailment medicine govorestat,...
.Novo Nordisk is actually proceeding its push right into genetic medicines, accepting compensate Nan...
.Innovent Biologics has produced the instance that its gate inhibitor-cytokine combination healthy p...
.A stage 3 test of Daiichi Sankyo as well as Merck & Co.'s HER3-directed antibody-drug conjugate ...
.5 months after Rakovina Therapeutics pivoted toward expert system, the cancer-focused biotech has a...
.Ascendis Pharma has actually become a potential danger to BioMarin's Voxzogo, stating period 3 grow...
.Though Alkeus Pharmaceuticals' oral eye ailment asset failed to substantially minimize geographical...
.Along with a trio of biotechs striking the Nasdaq on Friday, it was very easy to skip a smaller-sca...
.Invulnerable checkpoint preventions are the superheroes of cancer cells therapy. Medications like B...
.Invite to this week's Chutes & Ladders, our summary of notable leadership hirings, shootings as ...
.Regeneron is actually back along with long-lasting consequence for its LAG-3 inhibitor and PD-1 inh...
.AstraZeneca has actually shared a very early take a look at the performance of its own in-house ant...
.After revealing a stage 3 launch based on favorable midstage outcomes, iTeos and also GSK are lastl...
.The FDA ought to be much more open as well as collective to let loose a surge in approvals of uncom...
.It's an abnormally busy Friday for biotech IPOs, along with Zenas BioPharma, MBX and Bicara Therape...
.Atea Pharmaceuticals' antiviral has fallen short an additional COVID-19 trial, yet the biotech stil...
.Neurocrine Biosciences' schizophrenia system pivot has actually failed. The biotech was actually un...
.Sanofi has actually made an overdue entrance to the radioligand celebration, paying one hundred tho...